IMUGENE LIMITED — Board/Management Information 2016

Jan 3, 2016

==> picture [168 x 75] intentionally omitted <==

Imugene names Stuart Roberts as Head of Corporate Development

Melbourne, Australia, 4 January 2016: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce that Stuart Roberts has joined the company as Head of Corporate Development, effective immediately. Mr Roberts, who will be based in Sydney, will oversee Imugene’s Investor Relations programme globally as well as be involved in business development and corporate strategic planning.

Mr Roberts comes to Imugene after serving as Head of Investor Relations for the immunooncology drug developer Prima BioMed (ASX: PRR, Nasdaq: PBMD) between January and November 2015. During his time at Prima, that company experienced a notable improvement in market capitalisation and liquidity and was able to raise in excess of A$25m in new capital.

Prior to Prima BioMed Mr Roberts was for many years a leading sell-side analyst in the Australian equity market, pioneering science-based investment research focused on development-stage drug and medical device companies. At Southern Cross Equities from 2001, and then at Bell Potter Securities after that firm integrated Southern Cross Equities in 2011, and finally at Baillieu Holst from 2013 to 2015, he helped build strong, research-based franchises that were collectively responsible for in excess of A$600m in Life Science financings. Mr Roberts, who holds a Masters Degree in Finance from FINSIA, wrote for the investment publication The Intelligent Investor before commencing his investment banking career.

Paul Hopper, Executive Chairman of Imugene, welcomed Mr Roberts to the company, commenting, ‘Stuart Roberts is a true believer in the ability of biotechnology to create significant shareholder value as well as transform the lives of patients. His passion and enthusiasm for the sector, and knowledge of trends within it, is evident in every assignment he undertakes. I particularly appreciate Stuart’s ability to communicate sometimes complicated science to lay audiences as well as professionals. I look forward to working with Stuart as we take Imugene to the next stage of its growth’.

Mr Roberts said ‘Imugene has shown both pre-clinically and in the clinic that it is possible to create an off-the-shelf B cell peptide vaccine with potent anti-cancer properties. Having watched the development of cancer immunotherapy since the early 2000s, and its explosion to prominence after Yervoy’s FDA approval in 2011, I am convinced that the science behind HERVaxx has the potential to create serious upside for patients and shareholders. It is a privilege to be part of Team Imugene, working alongside talented Life Science professionals like Paul Hopper, Leslie Chong, Professor Ursula Wiedermann and Dr Axel Hoos’.

About Imugene and HER-Vaxx

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Imugene’s lead product is HER-Vaxx , a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a known and validated cancer target. HER-Vaxx’s successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer. For

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

further information, please visit www.imugene.com. Sign up to follow @TeamImugene on Twitter at http://www.twitter.com/TeamImugene.

For further information please contact:

Imugene:

Leslie Chong, Chief Operating Officer Tel: +61 458 040 433 (Australia), leslie.chong [at]imugene.com

Paul Hopper, Executive Chairman

Tel: +61 406 671 515 (Australia), receptogen[at]earthlink.net

Stuart Roberts, Head of Corporate Development Tel: +61 447 247 909, sroberts [at]imugene.com

Media:

Rudi Michelson, Monsoon Communications Tel: +61 3 9620 3333, rudim[at]monsoon.com.au

IMUGENE LIMITED Telephone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

2